Barchart.com's Chart of the Day - Pfenex
Related Stocks
 PFNX - Pfenex Inc
SymLastChgPct
PFNX8.72-0.18-2.02%

The Barchart Chart of the Day belongs to the biomedical company Pfenex (PFNX). I found the stock by sorting Barchart's Top Stocks to Own list first by the most frequent number of new highs in the last month then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 8/16 the stock gained 40.57%.

Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf'nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California.

PFNX

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 128.80+ Weighted Alpha
  • 100.61% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 18 new highs and up 45.33% in the last month
  • Relative Strength Index 79.32%
  • Technical support level at 9.36
  • Recently traded at 9.88 with a 50 day moving average of 6.89

Fundamental factors:

  • Market Cap $306 million
  • Revenue expected to grow 102.70% this year and another 100.40% next year
  • Earnings estimated to increase 59.30% this year, an additional 131.60% next year and continue to compound at an annual rate of 44.20% for the next 5 years
  • Wall Street analysts issued 1 strong buy and 2 buy recommendations on the stock
  • The individual investors following the stock on Motley Fool voted 6 to 1 that the stock will beat the market
  • 1,496 investors are monitoring the stock on Seeking Alpha